Response by Fordyce et al to Letter Regarding Article, “On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We appreciate the letter by Escober et al that highlights the fact that there was a greater temporal decline in renal function among patients taking warfarin than among those taking rivaroxaban from the ROCKET-AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).1 They assert that warfarin-related nephropathy contributes to worsening renal function on the basis of glomerular microbleeds and renal tubular obstruction and suggest that perhaps a novel anticoagulant such as rivaroxaban may be relatively more protective than warfarin in this setting.
However, the results …